Molecular-targeted therapy for motor neuron disease

Brain and Nerve

Volumn 61, Issue 8, 2009, Pages 891-900

  Banno, Haruhiko ^a   Katsuno, Masahisa ^a,b   Suzuki, Keisuke ^a   Iguchi, Yohei ^a   Adachi, Hiroaki ^a   Tanaka, Fumiaki ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Amyotrophic lateral sclerosis (ALS); Androgen receptor (AR); Leuprorelin acetate; Molecular targeted therapy; Spinal and bulbar muscular atrophy (SBMA)

Indexed keywords

ANDROGEN RECEPTOR; BUTYRIC ACID; CREATINE; ENZYME INHIBITOR; HEAT SHOCK PROTEIN; LITHIUM; PROTEASOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; SCAVENGER; SOMATOMEDIN; TAR DNA BINDING PROTEIN; TESTOSTERONE; TETRATHIOMOLYBDATE AMMONIUM; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ASTROCYTE; CELL ACTIVATION; DISEASE COURSE; DYSLIPIDEMIA; GENE MUTATION; HUMAN; KENNEDY DISEASE; MICROGLIA; MOLECULAR THERAPY; MOTOR NEURON DISEASE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; TESTOSTERONE BLOOD LEVEL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTYRATES; DNA-BINDING PROTEINS; DYSLIPIDEMIAS; FREE RADICAL SCAVENGERS; HEAT-SHOCK PROTEINS; HISTONE DEACETYLASES; HUMANS; LEUPROLIDE; MALE; MICE; MUSCULAR DISORDERS, ATROPHIC; MUTATION; NERVE GROWTH FACTORS; RECEPTORS, ANDROGEN; SUPEROXIDE DISMUTASE;

EID: 69549121961     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Miller RG, Mitchell JD, Lyon M, Moore DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 1: CD001447, 2007
2. Brain Nerve 59: 383-391, 2007
3. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130-133, 2006 (Pubitemid 44547757)
4. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, et al: TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351: 602-611, 2006 (Pubitemid 44708852)
5. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, et al: TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40: 572-574, 2008 (Pubitemid 351601218)
6. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, et al: TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319: 1668-1672, 2008
7. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, et al: Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11: 251-253, 2008 (Pubitemid 351311795)
8. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, et al: Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70: 1004-1009, 2008
9. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, et al: Glutamate receptors: RNA editing and death of motor neurons. Nature 427: 801, 2004
10. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, et al: Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67: 20-27, 2006 (Pubitemid 44305456)
11. Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, et al: Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler 9: 266-272, 2008
12. Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, et al: Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 213: 448-455, 2008
13. Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, et al: Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71: 1770-1775, 2008
14. Pitzer C, Krüger C, Plaas C, Kirsch F, Dittgen T, et al: Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 131: 3335-3347, 2008
15. Kadoyama K, Funakoshi H, Ohya W, Nakamura T: Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS. Neurosci Res 59: 446-456, 2007 (Pubitemid 350007815)
16. Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, et al: Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 80: 158-167, 2002 (Pubitemid 34614588)
17. Gordon PH, Cheung YK, Levin B, Andrews H, Doorish C, et al: A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 9: 212-222, 2008
18. Ohta Y, Kamiya T, Nagai M, Nagata T, Morimoto N, et al: Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis. J Neurosci Res 86: 3028-3037, 2008
19. Mosley RL, Gordon PH, Hasiak CM, Van Wetering FJ, Mitsumoto H, et al: Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. Amyotroph Lateral Scler 8: 235-242, 2007 (Pubitemid 47190228)
20. Kalmar B, Novoselov S, Gray A, Cheetham ME, Margulis B, et al: Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem 107: 339-350, 2008
21. Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, et al: Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 105: 2052-2057, 2008 (Pubitemid 351705154)
22. Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, et al: Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 10: 99-106, 2009
23. Kennedy WR, Alter M, Sung JH: Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18: 671-680, 1968
24. Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, et al: X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112: 209-232, 1989
25. Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, et al: Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129: 1446-1455, 2006 (Pubitemid 43999377)
26. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH.: Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352: 77-79, 1991
27. Tanaka F, Doyu M, Ito Y, Matsumoto M, Mitsuma T, et al: Founder effect in spinal and bulbar muscular atrophy (SBMA). Hum Mol Genet 5: 1253-1257, 1996 (Pubitemid 26335842)
28. Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, et al: Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 32: 707-710, 1992
29. Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, et al: Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 128: 659-670, 2005 (Pubitemid 40380200)
30. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, et al: Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35: 843-854, 2002 (Pubitemid 38787000)
31. Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, et al: Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35: 855-864, 2002
32. Chevalier-Larsen ES, O'Brien CJ, Wang H, Jenkins SC, Holder L, et al: Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24: 4778-4786, 2004 (Pubitemid 38668202)
33. Montie HL, Cho MS, Holder L, Tsvetkov AS, Finkbeiner S, et al: Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 18: 1937-1950, 2009
34. Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, et al: Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9: 768-773, 2003 (Pubitemid 36749228)
35. Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, et al: Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65: 140-150, 2009
36. Adachi H, Katsuno M, Minamiyama M, Sang C, Pagoulatos G, et al: Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 23: 2203-2211, 2003 (Pubitemid 36368908)
37. Katsuno M, Sang C, Adachi H, Minamiyama M, Waza M, et al: Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A 102: 16801-16806, 2005 (Pubitemid 41688857)
38. Tokui K, Adachi H, Waza M, Katsuno M, Minamiyama M, et al: 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet 18: 898-910, 2009
39. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, et al: 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11: 1088-1095, 2005 (Pubitemid 41486831)
40. Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, et al: Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 13: 1183-1192, 2004 (Pubitemid 38787000)
41. Banno H, Adachi H, Katsuno M, Suzuki K, Atsuta N, et al: Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 59: 520-526, 2006 (Pubitemid 43358073)